Glaukos Corporation GKOS reported fourth-quarter 2020 loss per share of 2 cents, significantly narrower than the Zacks Consensus Estimate of a loss of 32 cents. Notably, the company had delivered a loss per share of 6 cents in the prior-year quarter.For the full-year 2020, the company reported a loss of $1.15 per share, narrower than the Zacks Consensus Estimate of a loss of $1.41 per share. It had delivered loss per share of 10 cents in 2019.Revenues in DetailQuarterly net sales totaled $73.2 million, which surpassed the Zacks Consensus Estimate by 0.3%. On a year-over-year basis, revenues improved 11.2%.Glaukos Corporation Price, Consensus and EPS Surprise Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation QuoteFor the full-year 2020, the company’s net sales amounted to $224.9 million, down 5.1% from the previous year. The figure beat the consensus mark by 0.1%.Quarter DetailsGross profit in the fourth quarter was $53.6 million, up 7.4% year over year. Gross margin was 73.3% of net revenues, down 250 basis points (bps) on a year-over-year basis.Operating expenses declined 18.3% to $65 million on a year-over-year basis, courtesy of lower selling, general and administrative expenses.Operating loss in the quarter under review was $11.4 million, significantly narrower than the year-ago quarter’s loss of $29.7 million.Financial UpdateThe company exited the fourth quarter with cash and cash equivalents of $96.6 million, up from $80.9 million on a sequential basis.During the fourth quarter, total current assets totaled $469.4 million, compared with $454.4 million in the preceding quarter.First Quarter 2021 GuidanceFor first-quarter 2021, Glaukos projects net sales to grow around 15-20% on a year-over-year basis.Our TakeGlaukos exited the fourth quarter on a strong note. The company also reported an improvement in revenues in the quarter under review. Further, advancement in its market-expanding pipeline and execution of quite a few business development growth initiatives that include the Avedro buyout buoys optimism. Also, its U.S. Glaucoma franchise saw a solid recovery during the quarter under review courtesy of practices boosting their operational efficiency and rise in new patient demand with the easing of prior restrictions.However, the company faces cut-throat competition in the Medical Devices space. Glaukos witnessed a contraction in its gross margin in the quarter under review. Operating loss raises concern.Zacks RankGlaukos has a Zacks Rank #4 (Sell).Earnings of Other MedTech Majors at a GlanceSome better-ranked stocks in the broader medical space that have already announced their quarterly results are Hologic, Inc. HOLX, Abbott Laboratories ABT and AngioDynamics, Inc. ANGO, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which beat the Zacks Consensus Estimate by 6.6%. Fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss per share of 2 cents. Revenues of $72.8 million beat the consensus mark by 8%.Just Released: Zacks’ 7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.9% per year.These 7 were selected because of their superior potential for immediate breakout.See these time-sensitive tickers now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Hologic, Inc. (HOLX): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report Glaukos Corporation (GKOS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research